受新冠疫苗業務助推 BioNTech2021年Q4業績大幅增長 擬回購15億美元
格隆匯3月30日丨BioNTech(BNTX.US)公佈,受其與輝瑞公司合作的新冠疫苗的推動,該公司第四季度收益和收入大幅飆升,並表示將在未來兩年啟動一項高達15億美元的股票回購計劃。
公司2021年第四季度實現淨利潤31.7億歐元(合35.1億美元),高於上年同期的366萬歐元。該公司稱,營業收入從2020年第四季度的2.44億歐元躍升至47億歐元。當季總營收也大幅增長,從3.45億歐元增至55.3億歐元。
公司表示,2022年新冠肺炎疫苗訂單增至24億劑。該公司預計,今年的銷售收入將在130億歐元至170億歐元之間。BioNTech在2021年的強勁業績使其2022年的研發投資比前一年增加了約50%,料約為14億至15億歐元。除Covid-19外,公司重點關注腫瘤和傳染病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.